Browse the evidence

High resistant starch intake improves postprandial insulin and glucose regulation but may increase plasma TMAO levels, a biomarker for cardiovascular disease risk.

If you are insulin resistant, high resistant starch can help blunt blood sugar and insulin spikes after meals. However, be aware that it may also increase TMAO, a marker linked to heart disease risk in some studies. For most people, the metabolic benefits of better blood sugar control outweigh this risk, but those with existing cardiovascular issues should monitor this closely or consult a doctor.

In women, visceral adipose tissue (VAT) is significantly more strongly associated with insulin resistance and impaired insulin secretion than abdominal subcutaneous adipose tissue (SAT), whereas in men, both fat depots are associated with insulin resistance to a similar extent.

If you are a woman, carrying fat around your organs (visceral fat) is much more dangerous for your insulin sensitivity than carrying fat under your skin (subcutaneous fat). Men are less discriminating; both types of abdominal fat affect their insulin resistance similarly. Because waist size alone doesn't tell you where the fat is located, relying solely on it may underestimate metabolic risk in women. Focus on reducing overall adiposity, as visceral fat is the primary driver of insulin resistance in women.

Gender-affirming hormone therapy significantly reduces mental health morbidity, including depression and anxiety, in transgender individuals.

If you are transgender and experiencing significant distress related to your gender identity, accessing gender-affirming hormone therapy under medical supervision is strongly associated with significant improvements in mental health, including reduced depression and anxiety. While physical risks exist, they should be managed through careful monitoring and appropriate medication selection (e.g., transdermal estrogen for those at high thrombotic risk), as the mental health benefits are substantial.

Insomnia disorder is an independent risk factor for the development of mental health disorders, including depression, anxiety, and suicide, suggesting that treating insomnia may have preventive value for these conditions.

Treat insomnia seriously not just for sleep quality, but as a critical step in preventing depression and anxiety. Addressing sleep problems early may reduce the risk of developing these mental health conditions.

Cotadutide, a dual GLP-1 and glucagon receptor agonist, significantly improves hepatic parameters (AST, ALT, FIB-4, NFS, PRO-C3) and lipid profiles (triglycerides) in patients with type 2 diabetes and obesity, with effects on liver enzymes appearing independent of weight loss.

For individuals with type 2 diabetes and obesity, cotadutide (a dual GLP-1/glucagon agonist) offers significant improvements in liver health markers (like AST, ALT, and fibrosis scores) and triglyceride levels, potentially beyond what standard GLP-1 drugs like liraglutide achieve. This benefit appears linked to the glucagon component of the drug. Treatment involves daily subcutaneous injections, starting at a low dose and titrating up, which helps manage initial gastrointestinal side effects like nausea. Patients should discuss this option with their healthcare provider, especially if they have concerns about liver health or lipid profiles.

Sleep restriction (4-5 hours/night) impairs glucose metabolism and insulin sensitivity to levels similar to those seen in pre-diabetic or diabetic populations.

Chronic sleep restriction (4-5 hours/night) can impair your body's ability to regulate blood sugar to levels seen in pre-diabetic individuals. This happens even if you maintain a healthy weight. Prioritize 7-9 hours of sleep to protect your long-term metabolic health and reduce your risk of type 2 diabetes.

Higher Chinese visceral adiposity index (CVAI) is significantly associated with increased prevalence of cardiovascular disease (CVD) and diabetic kidney disease (DKD) in diabetic adults, independent of BMI.

For diabetic patients, tracking visceral fat risk via the Chinese Visceral Adiposity Index (CVAI) provides a more accurate prediction of heart and kidney disease risk than BMI alone. Clinicians should prioritize CVAI calculations to identify high-risk individuals for early intervention, particularly women who show a stronger association between CVAI and kidney disease.

Higher gut microbial alpha diversity (Shannon index and richness) and a higher abundance of specific butyrate-producing bacterial taxa are associated with lower insulin resistance (HOMA-IR) and a lower prevalence of type 2 diabetes.

Maintaining a diverse gut microbiome, particularly one rich in butyrate-producing bacteria, is linked to better insulin sensitivity and a lower risk of Type 2 Diabetes. While this study is observational, it suggests that dietary strategies supporting microbial diversity (often associated with high-fiber, plant-rich diets) may support metabolic health.

Industrial trans fatty acids (iTFA) promote cardiovascular disease risk through multiple mechanisms including increased LDL/HDL cholesterol ratio, activation of NF-κB-mediated inflammation, and induction of endoplasmic reticulum (ER) stress and oxidative stress.

Avoid industrial trans fats found in partially hydrogenated oils, as they raise bad cholesterol, lower good cholesterol, and trigger inflammation and cellular stress. While trans fats in natural dairy and meat exist, current evidence suggests they do not cause the same inflammatory or cellular damage as industrial versions, though moderation is still advised.

Excessive dietary fructose consumption (particularly from sugar-sweetened beverages) drives the development of Non-Alcoholic Fatty Liver Disease (NAFLD) and metabolic syndrome by stimulating hepatic de novo lipogenesis (DNL) and increasing VLDL secretion.

Limit intake of added sugars, specifically fructose and high-fructose corn syrup, found in sugar-sweetened beverages and processed foods. This is particularly critical if you have abdominal obesity or metabolic risk factors, as fructose uniquely drives liver fat accumulation and triglyceride production independent of total weight gain.

Insulin resistance (IR) and hyperinsulinemia accelerate muscle protein degradation and reduce synthesis, directly causing sarcopenia.

Managing blood sugar and insulin sensitivity is crucial for preserving muscle mass. If you have insulin resistance or pre-diabetes, addressing it may help prevent the accelerated muscle loss associated with aging and metabolic syndrome.

Regular exercise training suppresses chronic systemic inflammation by inhibiting the infiltration of inflammatory cells (neutrophils and M1 macrophages) into adipose tissue and skeletal muscle, thereby preventing tissue fibrosis and organ dysfunction associated with obesity and aging.

Engage in regular, moderate physical activity (like walking) rather than avoiding exercise due to fear of inflammation. This helps clear inflammatory cells from fat and muscle tissue, protecting your organs from age-related damage.

In Type 1 Diabetes (T1D), obesity and weight gain are increasingly common complications of intensive insulin therapy, contributing to insulin resistance and cardiovascular risk, but GLP-1 agonists and SGLT2 inhibitors show promise in mitigating weight gain.

If you have Type 1 Diabetes and are gaining weight despite insulin therapy, discuss adjunctive treatments like GLP-1 agonists or SGLT2 inhibitors with your doctor. These may help reduce insulin requirements and manage weight, addressing a common side effect of intensive insulin therapy.

Mitochondrial dysfunction in adipose tissue, characterized by reduced oxidative capacity and increased ROS, is a primary driver of insulin resistance and metabolic disease.

Maintaining healthy mitochondrial function in fat cells is crucial for managing insulin sensitivity and preventing metabolic diseases. Strategies to support this include regular exercise, caloric restriction, and potentially specific dietary compounds or medications that target mitochondrial health, as these can improve the body's ability to regulate glucose and lipids.

GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide) significantly reduce liver fat content and improve liver enzymes in patients with Type 2 Diabetes and NAFLD, with Semaglutide showing histological resolution of NASH in Phase II trials.

If you have Type 2 Diabetes and NAFLD, ask your doctor about GLP-1 receptor agonists like Semaglutide or Liraglutide. These injectable medications have been shown in clinical trials to reduce liver fat and improve liver inflammation, in addition to helping with weight and blood sugar control.

SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Ipragliflozin) improve liver fat content and liver enzymes in patients with Type 2 Diabetes and NAFLD, with some evidence of improving liver fibrosis.

If you have Type 2 Diabetes and NAFLD, SGLT2 inhibitors like Empagliflozin or Dapagliflozin may help reduce liver fat and improve liver enzymes. Discuss these options with your doctor, especially if you are already managing your blood sugar with other medications.

Erectile dysfunction in diabetic men is strongly associated with cardiovascular disease, often preceding coronary artery disease by 2-5 years, making ED a predictor of cardiac risk.

Erectile dysfunction is not just a sexual problem; it is a warning light for your heart. In diabetic men, ED often appears 2-5 years before heart disease symptoms. If you experience ED, request a cardiovascular risk assessment, as treating the underlying vascular issues can prevent future cardiac events.

High levels of proinflammatory cytokines TWEAK and TNF-α are associated with an increased risk of sarcopenia, while metabolic hormones IGF1, insulin, and adiponectin are associated with a decreased risk.

If you are over 60, getting your blood checked for inflammatory markers like TWEAK and TNF-α, and metabolic hormones like IGF1 and insulin, might provide a clearer picture of your muscle health risk than just looking at weight. High levels of these markers are linked to a much higher risk of sarcopenia. However, the good news is that lifestyle changes, specifically resistance training and whey protein supplementation, can significantly lower these inflammatory markers and improve muscle mass.

Extending the dose-escalation period or temporarily suspending dose increases when gastrointestinal adverse events occur improves tolerability and treatment persistence without compromising long-term efficacy.

If you feel sick after a dose increase, don't rush to the next one. Stay at the current dose for a few extra weeks or pause until you feel better. This helps your body adjust and keeps you on the medication longer.

Pharmacological management of persistent nausea with domperidone (preferred over metoclopramide) or other anti-emetics/prokinetics is an effective strategy for managing GLP-1 RA-induced nausea when dietary and titration strategies fail.

If diet changes aren't enough, ask your doctor about domperidone. It is often preferred over other anti-nausea drugs because it has fewer serious side effects. Use it as needed for nausea.

Excessive fructose consumption promotes nonalcoholic fatty liver disease (NAFLD) by acting as both a substrate and an inducer of hepatic de novo lipogenesis (DNL), leading to lipid accumulation and subsequent oxidative stress and inflammation.

Limit intake of added fructose, particularly from sugar-sweetened beverages and processed foods, as it directly drives liver fat accumulation and inflammation. Focus on whole foods where fructose is accompanied by fiber.

Fructose consumption negatively impacts peripheral tissues (gut, muscle, adipose) through interorgan cross-talk, leading to gut dysbiosis, visceral adiposity, and muscle insulin resistance/sarcopenia.

High fructose intake doesn't just hurt the liver; it can worsen gut health, increase belly fat, and reduce muscle insulin sensitivity. Reducing fructose supports whole-body metabolic health.

Exposure to blue-enriched light (peaking around 460 nm) during daytime hours acts as the strongest synchronizing agent for the human circadian rhythm by suppressing melatonin secretion, thereby enhancing alertness and cognitive performance.

Maximize exposure to bright, blue-enriched natural sunlight or high-quality artificial light during the morning and afternoon to anchor your circadian rhythm and boost daytime alertness. Conversely, minimize exposure to blue-emitting screens (phones, computers) in the 2-3 hours before bedtime to prevent melatonin suppression and sleep onset delays. Use night-mode filters on devices in the evening.

Chronic exposure to blue light at night, particularly from artificial sources like LED screens, disrupts circadian rhythms by suppressing melatonin, leading to sleep onset delays and increased health risks such as breast cancer in shift workers.

If you must use screens at night, use software that removes blue wavelengths (night shift mode) or wear amber-tinted glasses. Prioritize bright morning sunlight to help reset your clock after a night of disrupted light. For shift workers, strategic light exposure (bright light during shift, dark glasses on commute home) is critical.